EFTA00090721Set 9
2021-09-0352p13,922w
UNDER
FEDERAL RULE OF EVIDENCE 702 AND DAUBERT V. MERRELL DOW
PHARMACEUTICALS, INC., 509 U.S. 579 (1993) AND GRANT A DAUBERT
HEARING 15
A. This Court should reject the government ... Wigg, 889 A.2d 233 (Vt. 2005) 40
Daubert v. Merrell Dow Phanns., Inc., 509 U.S. 579 (1993) passim
Dougherty v. County ofSttffolk ... UNDER
FEDERAL RULE OF EVIDENCE 702 AND DAUBERT V. MERRELL DOW
PHARMACEUTICALS, INC., 509 U.S. 579 (1993) AND GRANT A DAUBERT
HEARING
A. This Court should reject the government
https://www.justice.gov/epstein/files/DataSet%209/EFTA00090721.pdf
EFTA00070837Set 9
2021-03-1241p13,013w
United States, 483 U.S. 171 (1987) 6
Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (1993) passim
deWit v. UPS Ground Freight ... preponderance of the evidence. See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 592 &
n.I 0 (1993) (citing Bourjaily v. United States, 483 U.S
https://www.justice.gov/epstein/files/DataSet%209/EFTA00070837.pdf
EFTA00074479Set 9
2007-05-0121p5,698w
EFTA00074480
TABLE OF AUTHORITIES
Page(s)
Cases
Daubert v. Merrell Dow Pharmaceuticals, Inc.,
509 U.S. 579 (1993) 12
Esquivel-Quintana v. Sessions,
137 S. Ct. 1562 (2017) 14
Grunewald ... Dauber( v. Merrell Dow
Pharmaceuticals, Inc., 509 U.S. 579 (1993).
12
EFTA00074494
issues, or misleading the jury, or by considerations of undue delay, [or] waste of time." Fed. R.
Evid
https://www.justice.gov/epstein/files/DataSet%209/EFTA00074479.pdf
EFTA00087774Set 9
2007-05-0121p5,654w
EFTA00087775
TABLE OF AUTHORITIES
Page(s)
Cases
Daubert v. Merrell Dow Pharmaceuticals, Inc.,
509 U.S. 579 (1993) 12
Esquivel-Quintana v. Sessions,
137 S. Ct. 1562 (2017) 14
Grunewald ... Dauber( v. Merrell Dow
Pharmaceuticals, Inc., 509 U.S. 579 (1993).
12
EFTA00087789
issues, or misleading the jury, or by considerations of undue delay, [or] waste of time." Fed. R.
Evid
https://www.justice.gov/epstein/files/DataSet%209/EFTA00087774.pdf
EFTA00024954Set 8
2013-02-0228p4,678w
proposed testimony is relevant. See Dauber!
v. Merrell Dow Pharm., Inc., 509 U.S. 579, 592 (1993); Nimely v. City of New York, 414 F.3d
381, 396 n.11
https://www.justice.gov/epstein/files/DataSet%208/EFTA00024954.pdf
EFTA00028165Set 8
2021-10-312p335w
under Federal Rule of Evidence 702 and Daubert v.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), Dkt. No. 386, and the other
outstanding issues that overlap with these
https://www.justice.gov/epstein/files/DataSet%208/EFTA00028165.pdf
EFTA00040107Set 9
2021-11-1011p3,312w
Evidence 702 and the standard in Daubert v.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). Dkt. No. 386. The Government filed
a response brief, Dkt. No. 397, and Defendant
https://www.justice.gov/epstein/files/DataSet%209/EFTA00040107.pdf
EFTA00027649Set 8
2021-11-101p172w
under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509
U.S. 579 (1993), Dkt. No. 386, and the other outstanding issues that overlap with these
https://www.justice.gov/epstein/files/DataSet%208/EFTA00027649.pdf
EFTA00027654Set 8
2021-11-101p172w
under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509
U.S. 579 (1993), Dkt. No. 386, and the other outstanding issues that overlap with these
https://www.justice.gov/epstein/files/DataSet%208/EFTA00027654.pdf
EFTA00014701Set 8
2021-11-017p1,772w
Supp. 3d
259, 263 (S.D.N.Y. 2019) (citing Daubert v. Merrell Dow Phanns., Inc., 509 U.S. 579, 593-94
(1993)).
But Rule 702 ultimately sets a "liberal" and "permissive" standard
https://www.justice.gov/epstein/files/DataSet%208/EFTA00014701.pdf
EFTA00087220Set 9
2021-11-017p1,774w
Supp. 3d
259, 263 (S.D.N.Y. 2019) (citing Daubert v. Merrell Dow Phanns., Inc., 509 U.S. 579, 593-94
(1993)).
But Rule 702 ultimately sets a "liberal" and "permissive" standard
https://www.justice.gov/epstein/files/DataSet%209/EFTA00087220.pdf
EFTA00094642Set 9
2021-11-1011p3,312w
Evidence 702 and the standard in Daubert v.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). Dkt. No. 386. The Government filed
a response brief, Dkt. No. 397, and Defendant
https://www.justice.gov/epstein/files/DataSet%209/EFTA00094642.pdf
EFTA00089904Set 9
2021-11-0117p4,502w
Supp. 3d
259, 263 (S.D.N.Y. 2019) (citing Dauber! v. Merrell Dow Pharms., Inc., 509 U.S. 579, 593-94
(1993)).
But Rule 702 ultimately sets a "liberal" and "permissive" standard
https://www.justice.gov/epstein/files/DataSet%209/EFTA00089904.pdf
EFTA00068501Set 9
2021-11-0117p5,289w
Supp. 3d
259, 263 (S.D.N.Y. 2019) (citing Dauber! v. Merrell Dow Pharms., Inc., 509 U.S. 579, 593-94
(1993)).
But Rule 702 ultimately sets a "liberal" and "permissive" standard
https://www.justice.gov/epstein/files/DataSet%209/EFTA00068501.pdf
EFTA00087203Set 9
2021-11-0117p5,289w
Supp. 3d
259, 263 (S.D.N.Y. 2019) (citing Dauber! v. Merrell Dow Pharms., Inc., 509 U.S. 579, 593-94
(1993)).
But Rule 702 ultimately sets a "liberal" and "permissive" standard
https://www.justice.gov/epstein/files/DataSet%209/EFTA00087203.pdf
EFTA00016471Set 8
2021-11-1011p3,312w
Evidence 702 and the standard in Daubert v.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). Dkt. No. 386. The Government filed
a response brief, Dkt. No. 397, and Defendant
https://www.justice.gov/epstein/files/DataSet%208/EFTA00016471.pdf
EFTA00094653Set 9
2021-11-1011p3,312w
Evidence 702 and the standard in Daubert v.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). Dkt. No. 386. The Government filed
a response brief, Dkt. No. 397, and Defendant
https://www.justice.gov/epstein/files/DataSet%209/EFTA00094653.pdf